Data / Form D filings / Neurovance, Inc.
Neurovance, Inc.: Form D filings
Neurovance, Inc., a biotechnology company in Cambridge, MA, filed 14 Form D notices with the SEC between 2012 and 2017. The latest, on January 6, 2017, reports $554,280 sold of a $554,280 offering to 1 investor.
Find out what Neurovance, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 43 THORNDIKE STREET, SUITE S1-3, Cambridge, MA, 02141
- Phone
- (617) 758-0300
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- No Revenues
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1544176
The full lists. Form D filings in Massachusetts: 1,533 rows, $76.65, or the new rows each week for $19 a month. Form D filings in Biotechnology: 1,568 rows, $78.40, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jan 6, 2017 | New notice | $554,280 | $554,280 | $0 | 1 | Dec 23, 2016 | sec.gov |
| Dec 1, 2016 | Amendment | $16,000,000 | $7,500,000 | $8,500,000 | 7 | Feb 24, 2016 | sec.gov |
| Jul 15, 2016 | Amendment | $6,000,000 | $6,000,000 | $0 | 7 | Feb 24, 2016 | sec.gov |
| Mar 2, 2016 | New notice | $4,000,000 | $1,000,000 | $3,000,000 | 7 | Feb 24, 2016 | sec.gov |
| Jun 29, 2015 | Amendment | $26,499,997 | $26,499,997 | $0 | 7 | Oct 11, 2012 | sec.gov |
| Mar 25, 2015 | Amendment | $20,000,002 | $20,000,002 | $0 | 7 | Oct 11, 2012 | sec.gov |
| Aug 29, 2014 | Amendment | $14,500,543 | $14,500,543 | $0 | 7 | Oct 11, 2012 | sec.gov |
| Aug 29, 2014 | Amendment | $14,500,543 | $14,500,543 | $0 | 7 | Oct 11, 2012 | sec.gov |
| Mar 31, 2014 | Amendment | $13,800,545 | $10,500,543 | $3,300,002 | 7 | Oct 11, 2012 | sec.gov |
| Oct 15, 2013 | Amendment | $7,500,540 | $7,500,540 | $0 | 7 | Oct 11, 2012 | sec.gov |
| Apr 24, 2013 | Amendment | $7,000,000 | $6,000,000 | $1,000,000 | 7 | Oct 11, 2012 | sec.gov |
| Oct 15, 2012 | New notice | $7,000,000 | $3,000,000 | $4,000,000 | 7 | Oct 11, 2012 | sec.gov |
| May 30, 2012 | Amendment | $478,064 | $478,064 | $0 | 7 | Mar 2, 2012 | sec.gov |
| Mar 16, 2012 | New notice | $478,064 | $163,463 | $314,601 | 6 | Mar 2, 2012 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Timothy J. Barberich | Director | |
| Anthony A. McKinney | Executive Officer | |
| Albert L. Sokol | Executive Officer | |
| Paul A. Weiss | Director | |
| Brigitte A. Smith | Director | |
| Jeffrey Bailey | Executive Officer, Director | |
| Daniel A. Omstead | Director | |
| Campbell A. Murray | Director | |
| William T. Pappafotopoulos | Executive Officer | |
| Brian L. Goff | Executive Officer, Director | |
| Gregg T. Beloff | Executive Officer |
Other biotechnology companies in Massachusetts that filed recently
- Zai Lab Ltd $249.9 million · Nov 9, 2026
- AI3 Bio, Inc. offering · Nov 4, 2026
- Tru Singular Health, Inc. $1 million · Oct 30, 2026
- 511 Therapeutics, Inc. $500,000 · Oct 30, 2026
- Elucid Bioimaging Inc. $56.2 million · Oct 27, 2026
- OrthoIQ, Inc. $1.1 million · Oct 23, 2026
- LeanBio Therapeutics, Inc. offering · Oct 22, 2026
- Quiver Holdings Inc. $3 million · Oct 21, 2026
- Axelyf, Inc. $2.6 million · Oct 13, 2026
- BIOVENTRIX, INC. $1.2 million · Oct 8, 2026
- Opus KSD, Inc. $680,801 · Oct 1, 2026
- Xact Bio, Inc. $10 million · Sep 28, 2026
- Way Biosolutions, Inc. $2 million · Sep 25, 2026
- AutoIVF, Inc. $1.5 million · Sep 25, 2026
- Typewriter Therapeutics, Inc. $56.3 million · Sep 21, 2026
Every Form D from the week of Jan 2, 2017 · All recent filings in Massachusetts · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what Neurovance, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.